ICHR's market value plummeted 49% while the company swung to massive operating losses despite revenue growth, indicating severe operational deterioration.
The dramatic decline in market capitalization from $1.28 billion to $658 million signals significant investor concern about the company's trajectory. Despite achieving 11.6% revenue growth, ICHR's operating performance collapsed with operating losses expanding over 400% to -$39.3M, suggesting fundamental issues with cost structure, pricing power, or operational execution that are overwhelming top-line gains.
ICHR presents a troubling paradox of growth masking operational distress—revenue increased 11.6% to $947.7M, but gross profit declined 15.1% and operating losses exploded from -$7.6M to -$39.3M. The company dramatically reduced share buybacks by 98% while doubling capital expenditures, suggesting cash flow pressures despite investing for growth. Rising interest expense (+75%) and SG&A costs (+20.5%) further pressured an already deteriorating cost structure, resulting in net losses deepening to -$52.8M and signaling serious operational challenges that investors should monitor closely.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 153.5% — review whether driven by operations, interest costs, or non-recurring items.
Capital expenditure jumped 105.1% — major investment cycle underway; assess returns on deployment.
Buyback activity reduced 98.2% — capital being redeployed elsewhere or cash conservation underway.
Interest expense surged 75.3% — significant debt increase or rising rates materially impacting earnings.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Receivables declined — improved collection efficiency or conservative revenue recognition.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Revenue growing 11.6% — solid top-line momentum, watch margins for quality of growth.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →